HeroSupport receives CE Mark for its VENUS SHELL radiotherapy device

Geneva-based medtech HeroSupport has received CE Mark certification for VENUS SHELL, its first commercial medical device, authorizing its deployment across the European Union and Switzerland. The certification, announced on International Women’s Day, marks the transition from clinical development to commercial expansion for the HUG spin-off, following seven years of research and clinical validation.

Breast cancer is the most commonly diagnosed cancer among women worldwide, affecting one in eight women over their lifetime. As survival rates improve, reducing long-term side effects from treatments such as radiotherapy has become a central challenge in oncology care.

VENUS SHELL addresses this challenge through a personalized, 3D-printed immobilization device designed for prone radiotherapy, a positioning technique in which the patient lies face down, allowing the treated breast to hang through a cut-out in the treatment table. This naturally separates the breast from the thoracic region, increasing the distance from the heart and lungs and reducing their radiation exposure compared with standard supine positioning. Each device is created from an individual patient’s anatomical model using advanced scanning and additive manufacturing.

The certification enables deployment in hospitals and radiation oncology centers across Europe. Swiss Medical Network has confirmed its intent to integrate VENUS SHELL across its clinical network. HeroSupport, which previously received a CHF 100,000 seed loan from the FONGIT Innovation Fund and participated in the Tech4Eva accelerator program, is now engaging with strategic partners and investors to scale operations in 2026.